Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 458

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials

Open access
Sawitzki, Birgit, Harden, Paul N, Reinke, Petra, Moreau, Aurélie, Hutchinson, James A, Game, David S, Tang, Qizhi, Guinan, Eva C, Battaglia, Manuela, Burlingham, William J, Roberts, Ian S D, Streitz, Mathias, Josien, Régis, Böger, Carsten A, Scottà, Cristiano, Markmann, James F, Hester, Joanna L, Juerchott, Karsten, Braudeau, Cecile, James, Ben, Contreras-Ruiz, Laura, van der Net, Jeroen B, Bergler, Tobias, Caldara, Rossana, Petchey, William, Edinger, Matthias, Dupas, Nathalie, Kapinsky, Michael, Mutzbauer, Ingrid, Otto, Natalie M, Öllinger, Robert, Hernandez-Fuentes, Maria P, Issa, Fadi, Ahrens, Norbert, Meyenberg, Christoph, Karitzky, Sandra, Kunzendorf, Ulrich, Knechtle, Stuart J, Grinyó, Josep, Morris, Peter J, Brent, Leslie, Bushell, Andrew, Turka, Laurence A, Bluestone, Jeffrey A, Lechler, Robert I, Schlitt, Hans J, Cuturi, Maria C, Schlickeiser, Stephan, Friend, Peter J, Miloud, Tewfik, Scheffold, Alexander, Secchi, Antonio, Crisalli, Kerry, Kang, Sang-Mo, Hilton, Rachel, Banas, Bernhard, Blancho, Gilles, Volk, Hans-Dieter, Lombardi, Giovanna, Wood, Kathryn J, Geissler, Edward K·2020·The Lancet

Abstract

Summary Background Use of cell-based medicinal products (CBMPs) represents a state-of-the-art approach for reducing general immunosuppression in organ transplantation. We tested multiple regulatory CBMPs in kidney transplant trials to establish the safety of regulatory CBMPs when combined with reduced immunosuppressive treatment. Methods The ONE Study consisted of seven investigator-led, single-arm trials done internationally at eight hospitals in France, Germany, Italy, the UK, and the USA (60 week follow-up). Included patients were living-donor kidney transplant recipients aged 18 years and older. The reference group trial (RGT) was a standard-of-care group given basiliximab, tapered steroids, mycophenolate mofetil, and tacrolimus. Six non-randomised phase 1/2A cell therapy group (CTG) trials were pooled and analysed, in which patients received one of six CBMPs containing regulatory T cells, dendritic cells, or macrophages; patient selection and immunosuppression mirrored the RGT, except basiliximab induction was substituted with CBMPs and mycophenolate mofetil tapering was allowed. None of the trials were randomised and none of the individuals involved were masked. The primary endpoint was biopsyconfirmed acute rejection (BCAR) within 60 weeks after transplantation; adverse event coding was centralised. The RTG and CTG trials are registered with ClinicalTrials.gov, NCT01656135, NCT02252055, NCT02085629, NCT02244801, NCT02371434, NCT02129881, and NCT02091232. Findings The seven trials took place between Dec 11, 2012, and Nov 14, 2018. Of 782 patients assessed for eligibility, 130 (17%) patients were enrolled and 104 were treated and included in the analysis. The 66 patients who were treated in the RGT were 73% male and had a median age of 47 years. The 38 patients who were treated across six CTG trials were 71% male and had a median age of 45 years. Standard-of-care immunosuppression in the recipients in the RGT resulted in a 12% BCAR rate (expected range 3·2-18·0). The overall BCAR rate for the six parallel CTG trials was 16%. 15 (40%) patients given CBMPs were successfully weaned from mycophenolate mofetil and maintained on tacrolimus monotherapy. Combined adverse event data and BCAR episodes from all six CTG trials revealed no safety concerns when compared with the RGT. Fewer episodes of infections were registered in CTG trials versus the RGT. Interpretation Regulatory cell therapy is achievable and safe in living-donor kidney transplant recipients, and is associated with fewer infectious complications, but similar rejection rates in the first year. Therefore, immune cell therapy is a potentially useful therapeutic approach in recipients of kidney transplant to minimise the burden of general immunosuppression. Funding The 7th EU Framework Programme.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(20)30167-7

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

See all 458

Metadata

Authors
Sawitzki, B., Harden, P. N., Reinke, P., Moreau, A., Hutchinson, J. A., Game, D. S., Tang, Q., Guinan, E. C., Battaglia, M., Burlingham, W. J., Roberts, I. S. D., Streitz, M., Josien, R., Böger, C. A., Scottà, C., Markmann, J. F., Hester, J. L., Juerchott, K., Braudeau, C., James, B., Contreras-Ruiz, L., van der Net, J. B., Bergler, T., Caldara, R., Petchey, W., Edinger, M., Dupas, N., Kapinsky, M., Mutzbauer, I., Otto, N. M., Öllinger, R., Hernandez-Fuentes, M. P., Issa, F., Ahrens, N., Meyenberg, C., Karitzky, S., Kunzendorf, U., Knechtle, S. J., Grinyó, J., Morris, P. J., Brent, L., Bushell, A., Turka, L. A., Bluestone, J. A., Lechler, R. I., Schlitt, H. J., Cuturi, M. C., Schlickeiser, S., Friend, P. J., Miloud, T., Scheffold, A., Secchi, A., Crisalli, K., Kang, S.-M., Hilton, R., Banas, B., Blancho, G., Volk, H.-D., Lombardi, G., Wood, K. J., & Geissler, E. K.
Venue
The Lancet
Publisher
Elsevier BV
Published
2020-05
Volume
395
Issue
10237
Pages
1627-1639
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W3026232934
Cited by
458
References
31
FWCI
54.56
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials. https://app.cochat.ai/papers/10.1016/s0140-6736(20)30167-7
The paper
Sawitzki, B., Harden, P. N., Reinke, P., Moreau, A., Hutchinson, J. A., Game, D. S., Tang, Q., Guinan, E. C., Battaglia, M., Burlingham, W. J., Roberts, I. S. D., Streitz, M., Josien, R., Böger, C. A., Scottà, C., Markmann, J. F., Hester, J. L., Juerchott, K., Braudeau, C., . . . Geissler, E. K. (2020). Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials. The Lancet. https://doi.org/10.1016/s0140-6736(20)30167-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.